9-Jan-2026
Insmed gains as preliminary 2025 revenue beats consensus
Seeking Alpha News (Fri, 9-Jan 10:54 AM ET)
Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating
TipRanks (Fri, 9-Jan 8:55 AM ET)
Insmed Announces Strong 2025 Results and Pipeline Progress
TipRanks (Fri, 9-Jan 7:33 AM ET)
Insmed’s 2025 Revenue Jumps 67% on Strong BRINSUPRI Launch, Eyes 2026 Milestones in Rare Diseases
Market Chameleon (Fri, 9-Jan 2:30 AM ET)
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Fri, 9-Jan 7:00 AM ET)
Insmed’s Top Brass Quietly Cashes In on a Multi-Million Dollar Stock Windfall
TipRanks (Thu, 8-Jan 9:03 PM ET)
PRNewswire (Thu, 8-Jan 10:00 AM ET)
Market Chameleon (Fri, 2-Jan 4:43 AM ET)
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Fri, 2-Jan 7:00 AM ET)
Business Wire (Mon, 29-Dec 9:29 PM ET)
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Insmed trades on the NASDAQ stock market under the symbol INSM.
As of January 9, 2026, INSM stock price climbed to $175.97 with 4,733,707 million shares trading.
INSM has a beta of 0.70, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.06 to the broad based SPY ETF.
INSM has a market cap of $37.53 billion. This is considered a Large Cap stock.
Last quarter Insmed reported $142 million in Revenue and -$1.75 earnings per share. This beat revenue expectation by $27 million and missed earnings estimates by -$.40.
In the last 3 years, INSM traded as high as $212.75 and as low as $16.04.
The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, VB, QQQ, VBK, VXF.
INSM has outperformed the market in the last year with a return of +167.8%, while the SPY ETF gained +19.0%. In the last 3 month period, INSM beat the market returning +7.0%, while SPY returned +3.7%. However, in the most recent 2 weeks INSM has underperformed the stock market by returning -1.1%, while SPY returned +0.5%.
INSM support price is $165.93 and resistance is $174.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM shares will trade within this expected range on the day.